EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Brain Microstructural Damage as Potential Biomarker of Immune Cell‐Associated Neurotoxicity Syndrome

Caterina Lapucci iD, Massimiliano Gambella, Emilio Cipriano, Anna Maria Raiola, Riccardo Varaldo, Anna Ghiso, M Centanaro, E Capello, A Schenone, Lucio Castellan, Laura Barletta, Emanuele Angelucci and 1 more

Journal of Neuroimaging · 2026

DOI: 10.1111/jon.70115 ↗

At a glance

Journal article in Journal of Neuroimaging, 2026. Written by Caterina Lapucci and 12 co-authors. Institution: IRCCS Ospedale Policlinico San Martino, Genoa, Italy. Major MEDLINE topics: Neurotoxicity Syndromes, Immunotherapy, Adoptive, Brain, Magnetic Resonance Imaging. 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project (1) MNESYS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Chimeric antigen receptor–engineered T‐cell (CAR‐T) therapy in hematological malignancies may be associated with severe complications, as Cytokine Release Syndrome (CRS) and Immune effector Cell‐Associated Neurotoxicity Syndrome (ICANS). The aim of the study is to investigate MRI‐derived macrostructural and microstructural features potentially able to identify patients at higher ICANS risk.

Methods

Forty‐two patients treated with CAR‐T from October 2020 to June 2025 performed brain MRIs before CAR‐T administration, including diffusion‐weighted imaging. A general linear model was used to compare patients who developed ICANS, CRS, or neither at baseline in terms of MRI macro‐ and microstructural features. A binary logistic regression analysis was performed to evaluate the role of microstructural features in predicting the risk of developing ICANS.

Results

Mean age 59.2 ± 13 years, 59.5% male; 21 (50%) patients received tisagenlecleucel, 21 (50%), axicabtagene ciloleucel or brexucabtagene autoleucel; 14 (33%) and 31 (73.8%) patients developed ICANS and CRS, respectively. At baseline MRI, fluid‐attenuated inversion recovery (FLAIR) white matter (WM) hyperintensities were detected in 41/42 (97.6%). No significant differences between patients who developed ICANS, CRS and neither both were observed in terms of FLAIR hyperintensities nor total brain volume at baseline. Fractional anisotropy extracted from FLAIR hyperintensities and WM areas without macroscopic abnormalities was a predictor of ICANS in the logistic regression model ( p = 0.03 and 0.02, respectively).

Conclusions

FLAIR hyperintensities and brain volume prior to CAR‐T were not informative, whereas the severity of WM microstructural (axonal) damage predicted ICANS risk. Greater axonal damage was associated with a higher likelihood of ICANS.

Subjects

MeSH terms (MEDLINE)

Neurotoxicity SyndromesImmunotherapy, AdoptiveBrainMagnetic Resonance ImagingCytokine Release SyndromeHumansMaleFemaleMiddle AgedBiomarkersHematologic NeoplasmsAgedDiffusion Magnetic Resonance Imaging

Author keywords

Cytokine Release Syndrome (CRS)Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS)MRIchimeric antigen receptor–engineered T‐cell (CAR‐T)diffusion

Substances

Biomarkerscell-associated neurotoxicity

Authors and institutions

  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
  • Anesthesiology and Intensive Care Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

ORCID profiles: Caterina Lapucci

Funding

  • Ministry of University and Research (MUR)
  • National Recovery and Resilience Plan (NRRP)
  • project (1) MNESYS

Cite

APA

Lapucci, C., Gambella, M., Cipriano, E., Raiola, A. M., Varaldo, R., Ghiso, A., Centanaro, M., Capello, E., Schenone, A., Castellan, L., Barletta, L., Angelucci, E., & Inglese, M. (2026). Brain Microstructural Damage as Potential Biomarker of Immune Cell‐Associated Neurotoxicity Syndrome. Journal of Neuroimaging. https://doi.org/10.1111/jon.70115

Vancouver

Lapucci C, Gambella M, Cipriano E, Raiola AM, Varaldo R, Ghiso A, et al. Brain Microstructural Damage as Potential Biomarker of Immune Cell‐Associated Neurotoxicity Syndrome. Journal of Neuroimaging. 2026. doi:10.1111/jon.70115

BibTeX
@article{Lapucci2026,
  author = {Lapucci, Caterina and Gambella, Massimiliano and Cipriano, Emilio and Raiola, Anna Maria and Varaldo, Riccardo and Ghiso, Anna and Centanaro, M and Capello, E and Schenone, A and Castellan, Lucio and Barletta, Laura and Angelucci, Emanuele and Inglese, Matilde},
  title = {Brain Microstructural Damage as Potential Biomarker of Immune Cell‐Associated Neurotoxicity Syndrome},
  journal = {Journal of Neuroimaging},
  year = {2026},
  doi = {10.1111/jon.70115}
}
Start for free →